Genomic Test May Predict Which Patients Would Benefit Most from Checkpoint Inhibition

To view this video please enable JavaScript and consider upgrading to a web browser that
supports HTML5 video

New genomic test could determine the patients who would benefit most from immunotherapy. Foundation Medicine, a molecular diagnostics company out of Cambridge, Massachusetts has created a test which determines a patient’s tumor mutation burden (TMB). Patients with high TMB have been shown to respond better to checkpoint inhibitors. The test has shown high tumor burden in cancers where checkpoint inhibitors are used in clinic as well as those where the therapy is not usually considered a viable option.